Del.icio.us
Google
Yahoo MyWeb
Facebook
Key People
Management
Friedhelm Blobel, President and Chief Executive Officer
No bio available. Add a bio.
Hans P. Schmid, President and Managing Director
No bio available. Add a bio.
Israel Rios, Chief Medical Officer
No bio available. Add a bio.
Cynthia W. Tuthill, Senior Vice President, Scientific Affairs & Chief Scientific Officer
No bio available. Add a bio.
Craig Halverson, Vice President, Regulatory Affairs & Quality Assurance
No bio available. Add a bio.
Eric J. Hoechstetter, Vice President, Legal Affairs
No bio available. Add a bio.
Randy J. McBeath, Vice President, Marketing
No bio available. Add a bio.
Randy McBeath, VP Marketing
No bio available. Add a bio.
Barbara Miercke, Director of Business Development
No bio available. Add a bio.
Sriram Vemuri, CTO
No bio available. Add a bio.
Hans Schmid, Managing Director
No bio available. Add a bio.
Cynthia Tuthill, Chief Scientific Officer
No bio available. Add a bio.
Shawn Singe, General Counsel
No bio available. Add a bio.
Board of Directors
Dean S. Woodman
No bio available. Add a bio.
John D. Baxter
No bio available. Add a bio.
Richard J. Hawkins
In 1983 Mr. Hawkins founded Pharmaco. As Chairman, President and Chief Executive Officer, he guided the growth of that organization to over 700 employees. Pharmaco offered a full range of clinical drug development services to the pharmaceutical industry, including Phase I-IV clinical trials and analytical chemistry services. The company merged with Applied Bioscience International. Mr. Hawkins managed their 2000 employee international Research & Development operations. More recently Pharmaco merged with PPD of Wilmington, NC to form PPDPharmaco, one of the largest clinical contract research organizations in the world.
After selling Pharmaco, Mr. Hawkins founded id2, a pharmaceutical and biotechnology research management company. Through his position as Chairman and CEO at id2, he has served as an advisor and mentor in the start-up of numerous companies, including Sensus Drug Development Corporation. Sensus, a biotechnology company, developed Growth Hormone Antagonists for use in acromegaly, the complications of diabetes, and regulation of growth hormone in the treatment of specific types of tumors. Mr. Hawkins co-founded Sensus and served as the Chairman. Sensus was sold to Pfizer.
Currently, he is Chairman and CEO of LabNow, Inc. LabNow, Inc. is a diagnostic device
company seeking to improve the quality of patient care and lower overall treatment costs through deployment of rapid, point-of-care, physician office-based diagnostic testing systems. The company, located in Austin, Texas, has licensed novel lab-on-a-chip sensor technology from The University of Texas (UT) that performs complex fluid analysis more quickly, more accurately and at lower cost than current methods. The micro fluidics sensor technology has broad medical, homeland security, environmental chemistry and process engineering application potential.
Mr. Hawkins is a cum laude graduate of Ohio University and resides in Austin, Texas.
Rolf H. Henel
No bio available. Add a bio.
Ira D. Lawrence
No bio available. Add a bio.
Jon S. Saxe
No bio available. Add a bio.
Phil VanderWerf
No bio available. Add a bio.
Rolf Henel
Rolf H. Henel has been a Director since June 1997. Mr. Henel has been a partner of Naimark & Associates, consultants to the health care industry, since 1994. Mr. Henel was a director and Treasurer of Bergen Community Blood Services from 1999 to 2005, Chairman of its Foundation from 2001 to 2004, and is the President of the Northern New Jersey Chapter of the American Association of Individual Investors. From 1978 to 1993, Mr. Henel was with American Cyanamid Company, most recently as President of Cyanamid International, Lederle Division. Mr. Henel was a director and Chief Operating Officer of Immunomedics, Inc. from 1996 to 1997. Mr. Henel holds a M.B.A. from New York University and a B.A. from Yale University. Mr. Henel is also a director of Penwest Pharmaceuticals Co., a pharmaceutical company, and Draxis Health Inc., a pharmaceutical company.
Richard Hawkins
Currently, Mr. Hawkins serves as the Chairman and CEO of LabNow, Inc., a privately-held company he founded in September 2003. LabNow is developing lab-on-a-chip sensor technology to be used in point-of-care diagnostic testing systems, including CD4 and viral load tests in resource scarce environments. From 1992 to 2000, Mr. Hawkins co-founded and served as Chairman of Sensus Drug Development, which developed and received regulatory approval for SOMAVERT, a growth hormone antagonist approved for the treatment of acromegaly and now marketed by Pfizer in both the United States and Europe. In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization (CRO) that in 1991 was merged with the predecessor of PPD-Pharmaco, becoming the cornerstone of one of the largest CROs in the world today. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University.
Jon Saxe
Mr. Saxe joined the Board in September 2002. From January 1995 to May 1999, he was President of Protein Design Labs (now PDL BioPharma) and continues to serve as a director. In 1999 he was also an Executive-in-Residence at Institutional Venture Partners, a venture capital firm. In addition, Mr. Saxe is a Director of Durect, First Horizon Pharmaceuticals, InSite Vision, Questcor Pharmaceuticals, and SciClone Pharmaceuticals and is Chairperson or a Director of several private companies, including Astex Therapeutics in Cambridge, UK. Mr. Saxe served as President of Saxe Associates, a biotechnology and pharmaceutical consulting firm, from May 1993 to December 1994. He served as President, Chief Executive Officer, and as a Director of Synergen (acquired by Amgen), a biopharmaceutical company, from 1989 to 1993. From 1984 until 1989, Mr. Saxe was Vice President, Licensing and Corporate Development at Hoffmann-LaRoche and Head of Patent Law at the company from 1978 until 1989. Mr. Saxe received his B.S. in Chemical Engineering from Carnegie-Mellon University, a J.D. from George Washington University School of Law, and his LL.M. from New York University School of Law.
Dean Woodman
Dean S. Woodman was elected Chairman of SciClone's Board of Directors in February 2004 and has been a Director since August 2000. Mr. Woodman was an investment banker for over four decades. From July 1989 to June 1999, he was a Managing Director of Furman Selz, an investment banking firm acquired in 1999 by ING Barings L.L.C. Mr. Woodman was a Managing Director in the investment banking group of Hambrecht & Quist (now JPMorgan Chase) from October 1984 to March 1988. He was a founding partner of Robertson Colman Stephens & Woodman, an investment banking firm, in 1978, and of Woodman Kirkpartrick & Gilbreath, an investment banking firm, in 1982. Mr. Woodman worked in the investment banking division of Merrill Lynch for 23 years where he spent 16 years as director of West Coast corporate finance until 1978. He is currently a director of MarineMax, Inc.
Ira Lawrence
Ira D. Lawrence, M.D. has been a Director since June 2005. Previously, Dr. Lawrence served as President and Chief Executive Officer of SciClone Pharmaceuticals, Inc. from June 2005 until June 2006. From 1995 to 2005, Dr. Lawrence was at Fujisawa Healthcare, Inc., most recently as the Senior Vice President of Research and Development. Fujisawa Healthcare Inc., was the U.S. subsidiary of Fujisawa Pharmaceutical Co. that recently merged with Yamanouchi Pharmaceutical Co. to form Astellas Pharma Inc. From 1993 to 1995, Dr. Lawrence served as Vice President of Research and Development at GenDerm Corporation. Dr. Lawrence was the Associate Director of Clinical Studies, Immunology at Fujisawa Healthcare, Inc. from 1991 to 1993. Prior to 1991, Dr. Lawrence practiced internal medicine and allergy/clinical immunology, most recently as the Assistant Chief of Staff at the Veterans Administration Lakeside Medical Center and Assistant Professor at Northwestern University Medical School. Dr. Lawrence earned his M.D. degree, from the Hahnemann Medical College (now Drexel University College of Medicine) and his B.A. from Temple University. Dr. Lawrence completed his internship and residency in internal medicine at Northwestern University and his fellowship at the Division of Allergy and Clinical Immunology at the Johns Hopkins University School of Medicine.
back to top
News & Blogs
View All News »- Latest
- Most Popular
- Submit a Story »
SciClone Announces Departure of Chief Financial Officer
Apr 10, 2008 - 0 comments
SciClone Pharmaceuticals on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.